NuWave Investment Management LLC Has $917,000 Stake in Merck & Co., Inc. (NYSE:MRK)

NuWave Investment Management LLC grew its stake in Merck & Co., Inc. (NYSE:MRK) by 1,066.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 10,943 shares of the company’s stock after buying an additional 10,005 shares during the period. Merck & Co., Inc. accounts for about 1.0% of NuWave Investment Management LLC’s holdings, making the stock its 28th largest position. NuWave Investment Management LLC’s holdings in Merck & Co., Inc. were worth $917,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRK. Oregon Public Employees Retirement Fund grew its position in Merck & Co., Inc. by 17,936.7% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 53,150,490 shares of the company’s stock worth $696,000 after purchasing an additional 52,855,811 shares during the last quarter. Norges Bank bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $2,166,688,000. Jennison Associates LLC lifted its holdings in shares of Merck & Co., Inc. by 323.1% during the 4th quarter. Jennison Associates LLC now owns 15,777,286 shares of the company’s stock worth $1,205,542,000 after acquiring an additional 12,048,406 shares during the period. BlackRock Inc. lifted its holdings in shares of Merck & Co., Inc. by 5.6% during the 4th quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock worth $14,868,587,000 after acquiring an additional 10,315,510 shares during the period. Finally, FMR LLC lifted its holdings in shares of Merck & Co., Inc. by 41.2% during the 1st quarter. FMR LLC now owns 11,111,444 shares of the company’s stock worth $924,139,000 after acquiring an additional 3,244,078 shares during the period. Institutional investors own 75.15% of the company’s stock.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 35,000 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $80.00, for a total value of $2,800,000.00. Following the completion of the transaction, the executive vice president now directly owns 106,064 shares of the company’s stock, valued at $8,485,120. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Frank Clyburn sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $77.73, for a total transaction of $1,943,250.00. Following the completion of the transaction, the executive vice president now directly owns 92,604 shares of the company’s stock, valued at $7,198,108.92. The disclosure for this sale can be found here. Insiders have sold a total of 276,718 shares of company stock valued at $23,257,469 over the last three months. 0.27% of the stock is currently owned by insiders.

A number of equities analysts have recently commented on the stock. UBS Group raised their price objective on shares of Tableau Software to $134.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Goldman Sachs Group set a $27.00 price objective on shares of Melco Resorts & Entertainment and gave the stock a “buy” rating in a report on Tuesday, May 28th. Atlantic Securities raised shares of Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a report on Monday, May 13th. They noted that the move was a valuation call. Credit Suisse Group assumed coverage on shares of Merck & Co., Inc. in a report on Thursday, July 11th. They set a “buy” rating and a $95.00 price objective for the company. Finally, Citigroup raised their price objective on shares of from GBX 1,300 ($16.99) to GBX 1,450 ($18.95) and gave the stock a “buy” rating in a report on Friday, June 21st. Two analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $90.36.

Shares of MRK stock opened at $84.07 on Wednesday. Merck & Co., Inc. has a 12-month low of $64.87 and a 12-month high of $87.07. The company has a market cap of $209.65 billion, a P/E ratio of 19.37, a P/E/G ratio of 1.73 and a beta of 0.57. The company’s 50-day moving average price is $83.15. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same period last year, the firm posted $1.06 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, equities research analysts predict that Merck & Co., Inc. will post 4.74 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.